Austin, Texas — Sensei Biotherapeutics Inc. said it has changed its corporate name to Faeth Therapeutics Inc. and will focus on advancing PIKTOR, an investigational oral therapy targeting the PI3K/AKT/mTOR pathway in cancer.
The company’s common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol “FTH” on June 16. The company also launched a new corporate website under the Faeth Therapeutics name.
The name change follows the company’s February acquisition of Faeth Therapeutics and a concurrent private placement that generated about $200 million in gross proceeds.
On June 10, stockholders approved the conversion of Series B preferred stock issued in connection with the acquisition and private placement. The outstanding Series B convertible preferred stock will automatically convert into common stock effective 5 p.m. ET on June 15, subject to certain beneficial ownership limits set by each holder.
“Starting tomorrow, we will begin trading on Nasdaq under our new name and ticker as a well-capitalized public company backed by a syndicate of leading life sciences investors, and focused on a clear set of clinical catalysts,” said Anand Parikh, Chairman and Chief Executive Officer. “For two decades, drugs that block a single node of the PI3K/AKT/mTOR pathway have been undone by the tumor’s ability to route around them. PIKTOR represents our answer to this challenge: an all-oral regimen that patients can take at home, designed to inhibit PI3K-alpha, mTORC1 and mTORC2 at once, close the routes tumors may use to escape, and potentially drive deeper, more durable suppression, with the potential for a best-in-class profile. We believe we now have the capital and the team to put that approach to the test, beginning with topline Phase 2 data in advanced endometrial cancer, expected in the second half of this year, and interim Phase 1b/2 data in HR+/HER2- advanced breast cancer, expected in 2027.”
PIKTOR is an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway. Faeth said the program remains on track for topline Phase 2 data in advanced endometrial cancer in the second half of 2026.
The company also expects interim Phase 1b/2 data in HR-positive, HER2-negative advanced breast cancer in 2027.
Effective June 12, the company appointed a new executive leadership team. Parikh, a co-founder of Faeth who has led the company since 2019, was named Chairman, President and Chief Executive Officer.
Brian Stephenson, Ph.D., CFA, who previously served as Faeth’s Head of Operations and Finance and as Chief Financial Officer of BridgeBio Pharma Inc., was appointed Chief Financial Officer. Oliver Maddocks, Ph.D., a co-founder of Faeth and cancer-metabolism researcher, serves as Chief Scientific Officer. Debbie Chirnomas, M.D., M.P.H., serves as Chief Medical Officer.
The company’s board consists of five members: Parikh, Bob Holmen, Phillip B. Donenberg, Stephen M. Hahn, M.D., and Saira Ramasastry.
Hahn, the 24th Commissioner of the U.S. Food and Drug Administration and a former Faeth director, and Ramasastry, a life sciences strategic adviser and public-company director, joined the board on June 12.
“In a career spent in oncology and at the FDA, I’ve learned how rarely a program pairs a high-prevalence target with a potentially differentiated mechanism,” said Stephen M. Hahn, M.D., the 24th Commissioner of the U.S. Food and Drug Administration and a member of the Company’s board of directors. “I believe Faeth’s multi-node, all-oral approach to the PI3K/AKT/mTOR pathway is scientifically rigorous and aimed at a real unmet need. I’m looking forward to guiding the company through this next stage of clinical development.”
